Get the Stockscreener App
2.60
1.17%
0.03
After Hours:
2.57
-0.03
-1.15%
Citius Pharmaceuticals Inc stock is traded at $2.60, with a volume of 100,000.
It is up +1.17% in the last 24 hours and down -38.79% over the past month.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
See More
Previous Close:
$2.57
Open:
$2.51
24h Volume:
100,000
Relative Volume:
0.45
Market Cap:
$20.09M
Revenue:
-
Net Income/Loss:
$-32.54M
P/E Ratio:
-13.00
EPS:
-0.2
Net Cash Flow:
$-29.06M
1W Performance:
-6.81%
1M Performance:
-38.79%
6M Performance:
-83.76%
1Y Performance:
-86.84%
1-Day Range:
$2.48
$2.74
1-Week Range:
$2.44
$2.85
52-Week Range:
$2.44
$26.75
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Name
Citius Pharmaceuticals Inc
Sector
Industry
Phone
(908) 967-6676
Address
11 COMMERCE DRIVE, CRANFORD, NJ
Compare CTXR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
2.60 | 20.09M | 0 | -32.54M | -29.06M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-30-21 | Initiated | Maxim Group | Buy |
Citius Pharmaceuticals Inc Stock (CTXR) Latest News
Citius Pharmaceuticals (NASDAQ:CTXR) Stock Price Down 5.1% – Here’s What Happened - Defense World
Citius Pharmaceuticals stock hits 52-week low at $2.52 By Investing.com - Investing.com Canada
Citius Pharmaceuticals stock hits 52-week low at $2.52 - Investing.com
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering - The Eastern Progress Online
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - The Eastern Progress Online
Analysts Hunt for Undervalued Biotech Stocks - Marketscreener.com
Citius Pharmaceuticals (FRA:47N0) Enterprise Value : €9.75 Mil (As of Nov. 28, 2024) - GuruFocus.com
Citius Pharmaceuticals (FRA:47N0) Earnings Yield (Joel Gree - GuruFocus.com
Citius Pharmaceuticals (FRA:47N0) 3-Year EPS without NRI Gr - GuruFocus.com
Citius Pharmaceuticals (FRA:47N0) Cyclically Adjusted Reven - GuruFocus.com
Citius Pharmaceuticals (FRA:47N0) Total Inventories : €0.00 Mil (As of Jun. 2024) - GuruFocus.com
Hemorrhoids Market Expected to Experience Major Growth by 2032, - openPR
Citius Pharmaceuticals, Inc. Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma - Marketscreener.com
Citius Pharmaceuticals Appoints John Laffey to the ARDS Scientific Advisory Board - Marketscreener.com
Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma - Marketscreener.com
Citius Pharmaceuticals, Inc. Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids - Marketscreener.com
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution - Marketscreener.com
Citius Pharmaceuticals, Inc. Appoints Jaime Bartushak as the Chief Financial Officer and Principal Financial Officer - Marketscreener.com
Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023 - Marketscreener.com
Citius Pharmaceuticals Engages Financial Advisor for Oncology Subsidiary Spinoff - Marketscreener.com
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration Regarding the Planned Resubmission of the BLA for LYMPHIR - Marketscreener.com
Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments - Marketscreener.com
Citius Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits - Quantisnow
Citius Pharma progresses with FDA on Mino-Lok approval By Investing.com - Investing.com Nigeria
Citius Pharmaceuticals (NASDAQ:CTXR) Earns Hold Rating from D. Boral Capital - Defense World
Citius Pharma progresses with FDA on Mino-Lok approval - Investing.com India
Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval - PR Newswire
Citius Pharma shares hit new low after reverse stock split - Kursiv Media
Citius Pharmaceuticals Stock Set to Reverse Split on Tuesday, November 26th (NASDAQ:CTXR) - Defense World
Citius Pharmaceuticals Announces 1-for-25 Reverse Stock Split - citybiz
Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split - The Malaysian Reserve
Citius Pharmaceuticals announces 1-for-25 reverse stock split - MSN
Citius Pharmaceuticals Announces 1-for-25 Reverse Stock Split to Maintain Nasdaq Listing | CTXR Stock News - StockTitan
Citius Pharmaceuticals stock hits 52-week low at $0.16 By Investing.com - Investing.com Australia
Citius Pharmaceuticals stock hits 52-week low at $0.16 - Investing.com India
Citius Pharmaceuticals reports positive early stage results of cancer combo treatment - MSN
Citius Pharmaceuticals (NASDAQ: CTXR) Announces Successful Closure of Offering - Defense World
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update - Defense World
Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share with Warrants - StockTitan
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering - The Malaysian Reserve
Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share | CTXR Stock News - StockTitan
What is HC Wainwright’s Estimate for CTXR FY2024 Earnings? - Defense World
Citius Pharmaceuticals stock hits 52-week low at $0.31 By Investing.com - Investing.com South Africa
Citius Pharmaceuticals stock hits 52-week low at $0.31 - Investing.com
Equities Analysts Set Expectations for CTXR FY2024 Earnings - MarketBeat
What is HC Wainwright’s Forecast for CTXR Q1 Earnings? - Defense World
Citius Pharmaceuticals granted extension to regain Nasdaq compliance - Investing.com
Citius Pharmaceuticals granted extension to regain Nasdaq compliance By Investing.com - Investing.com Australia
Q1 Earnings Forecast for CTXR Issued By HC Wainwright - MarketBeat
Citius Pharmaceuticals (NASDAQ:CTXR) Receives Buy Rating from HC Wainwright - MarketBeat
Citius Pharmaceuticals Inc Stock (CTXR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Citius Pharmaceuticals Inc Stock (CTXR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Webb Carol | Director |
Mar 04 '24 |
Option Exercise |
0.01 |
12,071 |
181 |
12,071 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):